Avicanna Applauds President Trump’s Executive Order to Reclassify Cannabis & Provides Scientific Update
(TSX:AVCN),(OTC US:AVCNF),(Other OTC:AVCNF),(Boerse Frankfurt – Freiverkehr:0NN),(Boerse Frankfurt – Freiverkehr:0NN.F), Avicanna's evidence-based pathway for cannabinoid-based medicine aligns with the executive order. Avicanna's 2025 advances across R&D, clinical development, and medical affairs. TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the […]